The antibody component: bnAbs in HIV cure
Antibodies have been ground-breaking in the therapy of autoimmune diseases and cancer and with the identification of new highly potent anti-HIV-1 broadly neutralising antibodies (bNAbs) in recent years. Antibodies will also play a key role in future HIV-1 treatment and prevention strategies. With their very long half-life, the activation of innate effector responses, and an enhancement of host immunity to HIV-1, these bNAbs can have several advantages compared to currently available antiretroviral therapy. Moreover, first results from studies in non-human primates as well as early-phase clinical studies suggest that bNAbs might have a key role in future approaches that aim to cure HIV-1.
Philipp Schommers, University of Cologne, Germany